BFC
ITRM

Bedel Financial Consulting’s Iterum Therapeutics ITRM Stock Holding History

Bedel Financial Consulting’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1
Closed – – 528
2022
Q1 		$0 Hold
1
– – ﹤0.01% 1017
2021
Q4 		$0 Hold
1
– – ﹤0.01% 1035
2021
Q3 		$0 Sell
1
-67
-99% -$825 ﹤0.01% 1006
2021
Q2 		$2K Buy
+68
New +$1.47K ﹤0.01% 887

Other funds holding ITRM

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

Bedel Financial Consulting's ITRM Position: Q2 2022 in Review

Bedel Financial Consulting sold out of Iterum Therapeutics (ITRM) in Q2 2022, closing a stake of 1 share.

Bedel Financial Consulting first reported a position in ITRM in Q2 2021 and held it in 4 quarters. The position peaked at $2K in Q2 2021. 38 funds tracked by Wall St. Rank hold ITRM as of Q2 2022.

  • Bedel Financial Consulting reported no remaining Iterum Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Bedel Financial Consulting sold 1 Iterum Therapeutics share in Q2 2022.
  • Bedel Financial Consulting first reported a position in Iterum Therapeutics in Q2 2021 and held it in 4 quarters.
  • Bedel Financial Consulting's Iterum Therapeutics position peaked at $2K in Q2 2021.
  • 38 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2022.

Based on Bedel Financial Consulting's 13F filing for Q2 2022, filed 4 Aug 2022.